Harvard group suggests PirB role in neuronal plasticity

27 August 2006

Researchers at the Harvard Medical School in the USA say that paired-immunoglobulin like receptor-B (PirB), previously thought to only play a role in immunity, may be involved in the development of neuronal stability associated with increasing age. The group explained that the transition from the highly-malleable plasticity of youthful neuronal connections to the more fixed linkages that develop with age, has never been properly explained but believes that the PirB receptor may play a role.

The report, which was published in the August 17 issue of the School's Science Press, showed that immature, PirB-deprived mice exhibited greater plasticity than brains endowed with the protein. Lead author, Josh Syken, the HMS' instructor in neurobiology, said: "our study of mutant mice lacking PirB function reveals that, at all ages, even during critical periods when circuits are prone to change, there are active molecular mechanisms that function to limit synaptic plasticity." He added that one way of repairing damaged regions of the brain may be to target local PirB levels.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight